 "Zydus acquires derma brand Melgain from Issar Pharma")
Hyderabad-based Suven Life Sciences has secured two patents -- one each from China and Mexico -- for its new chemical entities (NCEs) used in the treatment of neurodegenerative diseases.
With this, Suven has obtained 21 patents from China and 22 from Mexico.
These NCEs are being developed as therapeutic agents for cognitive disorders with high unmet medical needs and with a huge market potential globally, Suven CEO Venkat Jasti said in a statement on Tuesday.
Suven has three clinical stage compounds, a phase-2 undergoing candidate, phase-1 completed candidate and phase-1 undergoing candidate for Alzheimer's disease and Schizophrenia.
Other than these, the company has ten internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as attention deficit hyperactivity disorder (ADHD), dementia, depression, Huntington's disease, Parkinson's disease and pain.
